Pazopanib demonstrated its activity in a randomized, placebo-controlled, phase III trial, showing a significant improvement in progression free survival (PFS) and a favorable trend in OS in patients with advanced non-adipocytic STS who had previously been treated with anthracycline- or ifosfamide-based chemotherapy. 46 However, it is not specified if any cardiac AS were included in the study.
1
—
—